Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06473871 long-term efficacy and re-treatment in hypertrophic scars
NCT02205476Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2014
- Primary completion
- Jan 2015
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of EXC 001 in Hypertrophic Scar (HS) (2 arms), sponsored by Pfizer. Primary endpoints: Physician Scar Assessment Using Complete Patient and Observer Scar Assessment Scale at 52 weeks, Number of Participants With Clinically Significant Vital Sign Abnormalities at Week 15 and 2 more. Started Dec 2014; status: terminated.
02
Drugs
EXC 001
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT02205476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02205476.